GLOBAL ADVOCACY

The Stop TB Partnership unites over 1500 partners and leads global advocacy in the fight to End TB by 2030.

Stop TB mobilized millions of people through our annual World TB Day campaign and other events, achieved major reductions in the prices of TB diagnostics and medicines, and united and empowered people affected by TB, civil society, and communities by giving them a voice, platform, visibility and capacity.

The Global Plan to End TB 2016-2020 drives our work to put TB higher on the political agenda, mobilize resources, and create a paradigm shift in the global TB movement.

STRENGTHENING COMMUNITIES

People affected by TB and the grassroots organizations must be at the heart of all efforts to end TB.

Stop TB has the following areas of work: Challenge Facility for Civil Society (CFCS) grant programme; ensuring TB programmes are centred on human rights, gender sensitive interventions, and stigma reduction; increasing access of key and vulnerable populations to quality TB services; and investing in strengthening community systems and engagement in global, regional and national platforms.



TB Partnership



HELP BRING 画計画
THE TB EPIDEMIC 社会
TO AN END



TB is the world's leading infectious disease killer

Stop B Partnership

hosted by

UNOPS





WHO WE ARE

The Stop TB Partnership is a unique international body, which is a part of the United Nations family, that aligns all actors over the world to End TB.

The Stop TB Partnership ensures a voice for the TB community at the highest levels.

Various programmes identify and fund innovative approaches to find, treat and cure people affected by TB.

The Stop TB Partnership plays a key role in procuring TB drugs and diagnostics, including the roll-out of new tools across the world. Its market shaping strategy also helps to reduce prices, improve forecasting and prevent stock-outs for drugs.





TB REACH

TB REACH is a multi-lateral funding mechanism which provides grants to partners for testing innovative strategies and technologies aimed at increasing the number of people diagnosed and treated for tuberculosis (TB), decreasing the time to appropriate treatment and improving treatment

TB REACH combines fast-track, resultsbased financing and rigorous, external monitoring and evaluation (M&E) to produce results, so national governments and/or other donor agencies can scale up successful approaches and maximize their own investments.

GLOBAL DRUG FACILITY

The Global Drug Facility (GDF) is a one-stop, bundled procurement and supply mechanism for quality assured TB health products aimed at facilitating world-wide, equitable access to TB medicines and diagnostics across both public and private sectors.

Global Drug Facility combines strategic procurement and innovative logistics solutions, management and coordination of market activities for the full portfolio of TB medicines and diagnostics, technical assistance and capacity building for TB programmes in better pharmaceutical management practices, and accelerated uptake of new TB medicines, regimens, and

PARTNERING WITH THE PRIVATE SECTOR

In order to End TB by 2030 and reach the Sustainable Development Goals, it is imperative that the Stop TB Partnership meaningfully collaborate with the private sector to solve for critical, systemic barriers in the TB space. More importantly, Stop TB needs to harness both the public and private sector expertise and investment to work with local businesses and innovators to catalyze economic growth and sustainability in the developing countries.



KEY ACHIEVEMENTS

GDF (Global Drug Facility)



TB REACH



Between 2001 and 2015 **DELIVERED TB DRUGS**

25.8 million adult TB treatments **1.5 million** pediatric TB treatments

187, 853 treatments for drug resistant TB PROCURED TB DIAGNOSTICS

worth **US\$ 131 million** for more than **76 countries**

ENSURED

Bedaquiline, delamanid and new pediatric ormulations are available A stable and competitive supplier base

STRENTHENING COMMUNITIES



Between 2007 and 2016

AWARDED (CHALLENGE FACILITY) 131 grants through 7 rounds strengthening grass roots community systems

DEVELOPED

TB gender assessment tool and 9 key populations miniguides

STRENTHENED NETWORKS

and people centered approaches through the engagement of people affected by TB



Between 2010 and 2016

PROVIDED

142 grants in 46 countries for US\$ 95 million

OUR TB REACH GRANTEES DIAGNOSED

AND TREATED

Over 2 million people with TB, saving 600, 000 **lives** in the most underserved populations while working in close collaboration with National TB

TB REACH REPLENISHED for nearly CAD 100 million for 2016-2020

ADVOCACY



LAUNCHED THE GLOBAL PLAN TO END TB

SECURED

Heads of States commitment to increase TB financing and achieving the 90 90 90 targets

REVIEW ON ANTIMICROBIAL RESISTANCE includes MDR-TB as a lead priority


SUPPORTED

the 4th Global Fund Replenishment (\$12 billion) and increase its TB allocation from 16 to 18%

STOP TB PARTNERSHIP STRUCTURES

BOARD COMPOSITION

- Countries Affected by TB
- Communities Affected by TB
- Developing Country Non-Governmental
- Organization
- Developed Country
- Non-Governmental Organization
- Donors Foundations
- Multi-Lateral Organization Private Sector
- Technical Agencies
- Open Seats
- Working Groups



DONORS IN 2016

The Stop TB Partnership's work is made possible only through the support of the Partnership's many funders and partners. We appreciate their trust and gratefully acknowledge their support.

Bill & Melinda Gates Foundation DNA Genotek Inc. Eli Lilly & Co. Global Affairs Canada The Global Fund to Fight AIDS, Tuberculosis and Malaria **Kochon Foundation** UNITAID **United Nations Foundation** USAID

US Centers for Disease Control and Prevention

Global Drug-resistant TB Initiative (GDI)



www.stoptb.org